{"organizations": [], "uuid": "9ad6c92b135b392980dab670c6f700f11f8062b3", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 5}, "facebook": {"likes": 25, "shares": 25, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources/r/?m=02&d=20180103&t=2&i=1218980861&w=1200&r=LYNXMPEE0207V", "site_section": "http://feeds.reuters.com/reuters/healthNews\r", "section_title": "Reuters: Health News", "url": "https://www.reuters.com/article/us-novartis-kisqali/novartis-breast-cancer-therapy-gets-fda-breakthrough-designation-idUSKBN1ES0AZ", "country": "US", "domain_rank": 408, "title": "Novartis breast cancer therapy gets FDA breakthrough designation", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-03T08:56:00.000+02:00", "replies_count": 0, "uuid": "9ad6c92b135b392980dab670c6f700f11f8062b3"}, "author": "", "url": "https://www.reuters.com/article/us-novartis-kisqali/novartis-breast-cancer-therapy-gets-fda-breakthrough-designation-idUSKBN1ES0AZ", "ord_in_thread": 0, "title": "Novartis breast cancer therapy gets FDA breakthrough designation", "locations": [], "entities": {"persons": [{"name": "michael shields", "sentiment": "none"}, {"name": "maria sheahan", "sentiment": "none"}, {"name": "kisqali", "sentiment": "none"}], "locations": [{"name": "zurich", "sentiment": "none"}], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "novartis", "sentiment": "negative"}, {"name": "reuters staff", "sentiment": "none"}, {"name": "u.s. food and drug administration", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "ZURICH (Reuters) - Novartisâ€™s Kisqali (ribociclib) has won U.S. Food and Drug Administration breakthrough therapy designation for treating some breast cancer patients, the Swiss drugmaker said on Wednesday.\nThe designation covers initial endocrine-based treatment of pre- or perimenopausal women with hormone-receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer in combination with tamoxifen or an aromatase inhibitor.\nIt was based on results released last month from a Phase III MONALEESA-7 trial demonstrating Kisqali in combination with tamoxifen or an aromatase inhibitor significantly prolonged progression-free survival compared to endocrine therapy alone.\nReporting by Michael Shields; Editing by Maria Sheahan\n ", "external_links": [], "published": "2018-01-03T08:56:00.000+02:00", "crawled": "2018-01-03T09:11:30.000+02:00", "highlightTitle": ""}